Mylan Lawsuit Seeks To Force FDA's Hand On Lipitor Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Company files for an injunction requiring FDA to announce whether Ranbaxy's atorvastatin ANDA is ineligible for 180-day marketing exclusivity, a determination that could clear the path for approval of other applications starting June 28.